Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1Phase 1 1

Status

Withdrawn 1Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2CNS 1

Conditions

Breast Neoplasms 2Neoplasm Metastasis 1Brain Neoplasms 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
gancotamab × Clear all
NCT02735798 2017-05-04

64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets

University of California, San Francisco

Phase EARLY_PHASE1 Withdrawn
CNS

Brain Neoplasms

NCT01304797 2017-01-06

Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

Merrimack Pharmaceuticals

Phase 1 Unknown
75 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02213744 2017-01-06

HERMIONE

Merrimack Pharmaceuticals

Phase 2/3 Terminated
113 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡